XML 27 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets, Net
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, Net Intangible Assets, Net
The gross carrying amounts and net book value of our intangible assets are as follows:
 
 
 
December 31, 2019
 
Useful Life (In Years)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Accumulated Impairment Charges
 
Net Book Value
Ryanodex intangible
20
 
$
15,000

 
$
(2,454
)
 
$
—

 
$
12,546

Developed technology
5
 
8,100

 
(5,063
)
 
—

 
3,037

Total
 
 
$
23,100

 
$
(7,517
)
 
$
—

 
$
15,583



 
 
 
December 31, 2018
 
Useful Life (In Years)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Accumulated Impairment Charge
 
Net Book Value
Docetaxel product rights
10
 
$
11,220

 
$
(1,281
)
 
$
(9,939
)
 
$
—

Ryanodex intangible
20
 
15,000

 
(1,554
)
 
—

 
13,446

Developed technology
5
 
8,100

 
(3,443
)
 
—

 
4,657

Total
 
 
$
34,320

 
$
(6,278
)
 
$
(9,939
)
 
$
18,103



Amortization expense amounted to $2,520, $2,515, and $2,815, for the year ended December 31, 2019, 2018, and 2017, respectively.
Intangible Asset Impairment
During the year ended December 31, 2017, the Company experienced a decline in customer contracts and saw a drop in market pricing for Non-Alcohol Docetaxel Injection. Accordingly, the Company estimated the fair value of our Non-Alcohol Docetaxel Injection product and determined the carrying amount of the intangible asset was no longer fully recoverable, resulting in a pre-tax, non-cash asset impairment charge of $7.2 million during the year ended December 31, 2017.
On June 30, 2018, the Company implemented a restructuring initiative based on its assessment of the current product portfolio and made a decision to discontinue manufacture and distribution of Non-Alcohol Docetaxel Injection. The Company ceased selling the product by September 30, 2018. As a result, the Company recognized a pre-tax, non-cash asset impairment charge of $2.7 million during the year ended December 31, 2018.
Estimated Amortization Expense for Intangible Assets
Based on definite-lived intangible assets recorded as of December 31, 2019, and assuming that the underlying assets will not be impaired and that the Company will not change the expected lives of the assets, future amortization expenses are estimated as follows:
 
Estimated Amortization Expense
 
Year Ending December 31,
 
2020
$
2,666

2021
2,623

2022
1,369

2023
1,570

2024
1,570

All other
5,785

Total estimated amortization expense
$
15,583